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Background. There is a paucity of data on the pharmacokinetics of fixed-dose combination enteral antituberculosis treatment in critically 
ill patients.
Objectives. To establish the pharmacokinetic profile of a fixed-dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol 
given according to weight via a nasogastric tube to patients admitted to an intensive care unit (ICU).
Methods. We conducted a prospective, observational study on 10 patients (mean age 32 years, 6 male) admitted to an ICU and treated for 
tuberculosis (TB). Serum concentrations of the drugs were determined at eight predetermined intervals over 24 hours by means of high-
performance liquid chromatography.
Results. The therapeutic maximum plasma concentration (Cmax) for rifampicin at time to peak concentration was achieved in only 4 
patients, whereas 2 did not achieve therapeutic Cmax for isoniazid. No patient reached sub-therapeutic Cmax for pyrazinamide (6 were within 
and 4 above therapeutic range). Three patients reached sub-therapeutic Cmax for ethambutol, and 6 patients were within and 1 above the 
therapeutic range. Patients with a sub-therapeutic rifampicin level had a higher mean Acute Physiology and Chronic Health Evaluation II 
(APACHE II) score (p=0.03) and a lower estimated glomerular filtration rate (GFR) (p=0.03).
Conclusions. A fixed-dose combination tablet, crushed and mixed with water, given according to weight via a nasogastric tube to patients 
with TB admitted to an ICU resulted in sub-therapeutic rifampicin plasma concentrations in the majority of patients, whereas the other 
drugs had a more favourable pharmacokinetic profile. Patients with a sub-therapeutic rifampicin concentration had a higher APACHE 
II score and a lower estimated GFR, which may contribute to suboptimal outcomes in critically ill patients. Studies in other settings have 
reported similar proportions of patients with ‘sub-therapeutic’ rifampicin concentrations.
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The global increase in the incidence of tuberculosis 
(TB), especially in conjunction with the HIV 
pandemic, has resulted in an increased number of 
hospital admissions due to TB.[1] Previous studies have 
shown that approximately 1.5% of hospitalised adults 
with active TB develop respiratory failure requiring admission to an 
intensive care unit (ICU).[2,3] Mortality among these patients can be as 
high as 65%.[4]
A myriad of factors may influence pharmacokinetics in patients 
admitted to the ICU. Drug absorption is generally decreased. Tarling 
and co-workers found sub-therapeutic plasma levels of enterally 
administered paracetamol, and showed that gastric emptying time 
varied significantly between patients.[5] Patients in the ICU often have 
increased vascular permeability secondary to cytokine release, as 
well as hypo-albuminaemia, which alter the volume of distribution. [6] 
Furthermore, drug metabolism and excretion may be profoundly 
affected by hepatic and renal dysfunction.[6]
There are also certain factors specific to patients with TB in the 
ICU that may influence pharmacokinetics, the chief of which is that 
patients are fed continuously. Drugs are therefore not administered 
on an empty stomach, as is recommended for some anti-TB drugs 
to achieve optimal absorption.[7] Interestingly, evidence suggests 
that the functional absorptive area of the intestines of patients 
with tuberculosis is also decreased when compared with healthy 
volunteers, which in turn results in decreased absorption.[8]
There are currently no published studies on absorption rates and 
pharmacokinetic patterns of anti-TB drugs in patients requiring 
intensive care. The aim of this pilot study was therefore to assess 
whether therapeutic plasma drug concentrations are achieved 
following nasogastric administration of first-line fixed-dose 
combination standard anti-TB treatment in critically ill patients.
Methods
Study design and patient selection
All adult patients (≥18 years) admitted between April 2010 and June 
2011 to the Medical ICU of Tygerberg Academic Hospital (TBAH), 
Western Cape, South Africa, and treated for pulmonary tuberculosis 
for at least 7 days were candidates for this prospective observational 
study, provided a nasogastric tube was in situ on the day of enrolment. 
Exclusion criteria included the use of concomitant intravenous (IV) 
TB treatment, an estimated glomerular filtration rate (GFR) of 
<50 ml/min, evidence of hepatic dysfunction (alanine transaminase 
(ALT) or aspartate transaminase (AST) >3 times the upper limit 
of normal), bowel surgery in the preceding 7 days, and pregnancy. 
TBAH is a 1 200-bed tertiary hospital, one of two academic referral 
centres in the Cape Town area, and renders a service to a population 
of approximately 1.5 million. In 2010 the incidence of pulmonary TB 
in this population was 981 cases per 100 000.[9] The Health Research 
Ethics Committee of Stellenbosch University approved the study. 
Written informed consent was obtained by proxy on enrolment.
Clinical parameters and general special investigations
Apart from general demographic information, the number of days 
on treatment and the presence of co-morbid illnesses and/or sepsis 
were actively sought.[10] Acute Physiology and Chronic Health 
Evaluation (APACHE) II scores,[11] the presence of bowel sounds and 
co-administration of sedatives and inotropic agents were documented 
on enrolment. As per standard procedure in the unit, 4-hourly gastric 
aspirates were performed on patients receiving enteral feeds (to 
measure residual volume). Serum creatinine, bilirubin, ALT and AST 
were measured, and the GFR calculated according to the Cockcroft 
and Gault estimation.[12]
Administration of antituberculosis medication
All patients received Rimstar 4-FDC (Sandoz, Kempton Park, South 
Africa), which is a combination of rifampicin 150 mg, isoniazid 75 mg, 
pyrazinamide 400 mg and ethambutol 275 mg. The ideal body weight 
for each patient was calculated according to the Devine formula,[13] 
and patients were given 2 tablets for weight <37 kg, 3 for weight 38 - 
54 kg, 4 for weight 55 - 70 kg and 5 for weight >70 kg. The tablets were 
crushed and given with 20 ml tap water via a nasogatric tube.
Plasma drug concentration sampling and analysis
Plasma rifampicin, isoniazid and pyrazinamide concentrations were 
measured before and 0.5, 1.25, 2.25, 3.5, 5.0, 12 and 24 hours after drug 
administration. Blood was collected into 10 ml ethylenediaminetetra-
acetic acid (EDTA)-containing blood sampling tubes, embedded 
into crushed ice immediately and transported to the bio-analytical 
laboratory within 1 hour.
Rifampicin concentrations were measured by means of 
precipitation of plasma proteins with a mixture of acetonitrile and 
methanol. Quantification was performed by a high-performance 
liquid chromatography (HPLC) method in conjunction with triple 
quadrupole mass spectrometry (MS/MS) detection (quantification 
range 1 - 15 µg/ml). Isoniazid levels were assessed by the precipitation 
of plasma proteins with 10% trichloroacetic acid (TCA) solution, 
followed by derivatisation with 1% cinnamaldehyde and ultraviolet 
(UV) detection at 340 nm (quantification range 1 - 25 µg/ml). In 
the case of pyrazinamide, precipitation of plasma proteins was 
achieved with 10% TCA solution; 30 µl of the supernatant was 
injected into the HPLC with UV detection at 269 nm (quantification 
range 10 - 150 µg/ml). Ethambutol levels were measured by means 
of precipitation of plasma proteins with acetonitrile at a ratio of 
plasma/organic solvent of 1:3. Quantification was performed by an 
HPLC method in conjunction with MS/MS (quantification range 
1 - 15 µg/ml). The acetylator status of patients for the metabolism 
of isoniazid was determined by means of phenotyping, and patients 
were categorised as slow, intermediate or fast acetylators according to 
accepted criteria.[14-17]
Pre-dose concentration, maximum plasma concentration (Cmax), 
time to peak concentration (tmax) and area under the curve for 24 
hours (AUC0-24h) were documented, and concentrations compared 
with data from healthy volunteers in the literature.[7]
Statistical aspects
Descriptive statistics and Fisher’s exact tests (where indicated) were 
performed on dichotomous categorical variables, and t-tests on 
continuous data. Unless stated otherwise, data are displayed as means 
and standard deviations (SDs).
Results
Patients
Over a 1-year period 35 patients admitted to the medical ICU 
were screened, and the first 10 patients (32 (SD 12) years, 6 male) 
who fulfilled the criteria entered into the study. Of these, 1 patient 
died in the ICU. The mean ICU admission duration was 19.9 days 
(range 6 - 33 days), and the mean APACHE II score was 21 (SD 6). 
Indications for ICU admission included respiratory failure (n=8), 
life-threatening haemoptysis (n=1) and a drug overdose (n=1). 
At the time of blood sampling, all patients required ventilatory 
support, either invasive (n=9) or non-invasive (n=1). Only 1 patient 
had feeding interrupted at the time of inclusion and 9 received 
enteral feeding. None of the study patients had large residual 
volumes at 4 hours after feeds (mean volume 2.22 ml), which 
suggested that gastric emptying was adequate.
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Measured plasma concentrations
Therapeutic Cmax for rifampicin at tmax was achieved in only 4 
patients (Table 1). Only 2 patients did not achieve therapeutic Cmax 
for isoniazid, and 5 patients had Cmax levels above the therapeutic 
range. No patient reached sub-therapeutic Cmax for pyrazinamide, 
6 patients falling within and 4 above the therapeutic range. Three 
patients reached sub-therapeutic Cmax for ethambutol, and 6 patients 
were within and 1 above the therapeutic range. The acetylator status 
was slow and indeterminate in the 2 cases in which sub-therapeutic 
isoniazid concentrations were measured (Table 1). The plasma 
concentrations over time (AUC0-24h) for the various drugs are given 
in Figs 1 - 4.
Patients with sub-therapeutic rifampicin plasma levels had a 
significantly higher APACHE II score and a lower estimated GFR 
than patients with therapeutic levels (Table 2). The low patient 
numbers precluded similar comparison with the other drugs.
Discussion
To the best of our knowledge, this is the first study to investigate the 
pharmacokinetic profile of a fixed-dose combination of rifampicin, 
isoniazid, pyrazinamide and ethambutol given according to weight via 
a nasogastric tube to patients with TB admitted to the ICU. In this pilot 
study we found sub-therapeutic rifampicin levels in more than half 
of all cases. The other drug components, pyrazinamide in particular, 
had more favourable pharmacokinetic profiles. Patients with a sub-
therapeutic plasma rifampicin level had a significantly higher APACHE 
II score and lower estimated GFR when compared with patients with 
therapeutic concentrations, but similar gastric emptying.
Rifampicin and isoniazid remain the cornerstone drugs in the 
treatment of tuberculosis and combination treatment is essential to 
reduce drug resistance.[18] Of the four first-line drugs, only rifampicin 
is available as an IV injection in much of the developing world. 
The pharmacokinetic profile of anti-TB drugs has been extensively 
investigated outside the intensive care environment. It has been 
shown that there is a dose-dependent relationship with clinical 
outcomes in respect of rifampicin.[19] Furthermore, McIlleron and 
co-workers demonstrated a wide variation in plasma concentrations 
of rifampicin, with almost 70% of the study group at the lower end 
(<8  µg/l) and 22% at the very low end (<4 µg/l) of the therapeutic 
range. [20] Kimerling et al. reported very similar findings, 64% of 
subjects having levels below 8 µg/l for rifampicin.[21] In a cohort of 
patients, the majority of whom were HIV-infected, Chideya et al. 
Table 1. Therapeutic concentrations (Cmax, µg/ml) achieved and acetylator type (N=10)
Drug levels achieved
Rifampicin Isoniazid Pyrazinamide Ethambutol
Therapeutic range 8 - 24 3 - 6 (A) 20 - 50 2 - 6
Patient
1 1.2 2.4 (S) 29.4 2.1
2 7.3 3.9 (F) 40.4 3.9
3 6.1 4.4 (F) 51.0 5.0
4 2.8 6.2 (I) 69.2 6.0
5 9.6 9.0 (S) 118.3 1.5
6 11.7 8.7 (I) 75.4 9.0
7 14.1 9.7 (I) 65.2 3.0
8 5.6 3.5 (I) 36.8 1.3
9 9.6 8.8 (I) 48.0 2.0
10 3.5 1.4 (X) 30.2 1.0
A = acetylator type: S = slow; I = intermediate; F = fast; X = indeterminate.
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Fig. 1. Rifampicin plasma concentration over time (0 - 24 hours, mean (SD), 
N=10). Cmax=6.37μg/ml, tmax=1.25 h, AUC(0-24)=60.70 μg X h/ml.
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Fig. 2. Isoniazid plasma concentration over time (0 - 24 hours, mean (SD), 
N=10). Cmax=5.20 μg/ml, tmax=0.5 h, AUC(0-24)=19.97 μg X h/ml.
RESEARCH
397  June 2013, Vol. 103, No. 6  SAMJ
found that 84% of patients had levels below 8 µg/l.[22] These data are 
comparable to our findings.
Several mechanisms, which are not necessarily specific to the 
critically ill patient, may contribute to sub-therapeutic plasma 
concentrations of rifampicin. Previous studies demonstrated that there 
is a decrease in functional absorptive area of the intestines in patients 
with TB.[8,23] This is especially true in patients with multidrug-resistant 
TB.[23] It has been demonstrated that intestinal paracellular absorption 
in patients with active pulmonary TB is markedly decreased, but 
that this is unlikely to contribute significantly to lower plasma levels, 
as it represents less than 5% of the total absorptive area of the small 
intestine.[24] The patients in our study group were given rifampicin in 
a combination tablet either on an empty stomach with the addition 
of an antacid (sucralfate) or while given continuous feeds. It has been 
shown that antacids do not influence peak drug levels of rifampicin, 
but a high-fat meal can reduce Cmax by 36% and nearly double 
tmax.[25] The 4-hour nasogastric aspirates are a surrogate marker of 
gastric emptying, and higher volumes aspirated suggest slower gastric 
emptying.[26] Of note is the fact that we found no significant correlation 
between a higher volume of 4-hourly nasogastric aspirates and sub-
therapeutic rifampicin levels. Data from Ruslami and co-workers 
previously suggested that the concentrations of rifampicin in ambulant 
patients receiving rifampicin orally were somewhat higher than those 
in patients who received drugs (at a similar dose) via a nasogastric tube, 
suggesting that adsorption of rifampicin to plastics, and potentially to 
nasogastric tubing, play a role.[27]
The association of a lower plasma rifampicin concentration 
with a lower estimated GFR may very well be spurious, as only 
approximately 15% of rifampicin is renally excreted, and theoretically 
a lower GFR should result in higher plasma concentrations.[19] The 
small sample size and the fact that patients with an estimated GFR of 
<50 ml/min were excluded confounds this apparent association, as a 
lower GFR may very well be an indicator of general disease severity.
The sub-therapeutic plasma concentrations observed in our 
study strongly support the weight of evidence that use of IV 
rather than oral rifampicin in the critically ill TB patient should 
become routine practice, given the drug’s apparent safety in higher 
doses. [27,28] Interestingly, in a very recent study, a 33% higher dose 
of IV rifampicin (600 mg v. 450 mg), led to a three times higher 
geometric mean area under the time-concentration curve up to 6 
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Fig. 3. Pyrazinamide concentration over time (0 - 24 hours, mean (SD), 
N=10). Cmax=51.2 μg/ml, tmax=0.5 h, AUC(0-24)=475.23 μg X h/ml.
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Fig. 4. Ethambutol concentration over time (0 - 24 hours, mean (SD), N=10). 
Cmax=3.02 μg/ml, tmax=1.25 h, AUC(0-24)=26.18 μg X h/ml.
Table 2. Patients with therapeutic rifampicin plasma concentrations v. patients with sub-therapeutic concentrations
Therapeutic Sub-therapeutic p-value
No. of patients 4 6 NA
Days in ICU*, mean (SD) 15.5 (10.2) 12.0 (9.4) 0.59
Days on treatment, mean (SD) 25.8 (24.3) 37.8 (69.7) 0.79
APACHE II score, mean (SD) 16.6 (1.7) 25.2 (6.1) 0.03
Serum albumin (g/l), mean (SD) 25.3 (2.2) 25.7 (4.2) 0.86
Serum ALT (U/l), mean (SD) 49.0 (55.6) 51.2 (30.5) 0.93
Estimated GFR (ml/min/1.73 m2), mean (SD) 180.0 (73.5) 102.3 (11.9) 0.03
Inotropic support, n 0 1 NA
IV sedation, n 4 2 NA
Continuous feeding, n 5 4 NA
Nil by mouth, n 1 0 NA
Gastric residual volume (ml)†, mean (SD) 14.0 (10.7) 11.5 (11.2) 0.73
ICU = intensive care unit; SD = standard deviation; APACHE II = Acute Physiology and Chronic Health Evaluation II; ALT = alanine transaminases; GFR = glomerular filtration rate; IV = 
intravenous; NA = not applicable.
*At time of sampling.
†Mean 4-hourly aspirate.
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hours after the dose and, importantly, to maximum plasma and 
cerebrospinal fluid concentrations.[28]
The pharmacokinetic profile of isoniazid varies greatly from patient 
to patient on the basis of acetylator status, as the drug is cleared mostly 
by acetylation.[4] Slow acetylators obtain higher plasma levels and 
better therapeutic responses. Interestingly, we found little correlation 
between acetylator status and plasma levels – in fact, one of the 2 
patients with sub-therapeutic isoniazid levels was a slow acetylator.
We observed a mortality rate well below published figures.[4] 
Although the small sample size complicates meaningful comparison 
with previous studies, it remains likely that this observation was 
merely a selection bias, as we only included patients with preserved 
renal and liver function.
Our study has certain limitations. Our sample size was small 
and many factors may have influenced the pharmacokinetics, 
including extremes of weight and days on treatment.[29] The lack 
of a control group may also be viewed as a limitation of our study. 
We used historical pharmacokinetic data in our analysis, as it was 
deemed impractical and unethical to subject 10 healthy volunteers 
to 7 days of TB treatment, a nasogastric feeding tube and 24 hours of 
pharmacokinetic sampling.
In conclusion, we found that a fixed-dose combination tablet (Rimstar 
4-FDC; Sandoz) given according to weight via a nasogastic tube to 
patients admitted to the ICU resulted in sub-therapeutic rifampicin 
plasma concentrations in the majority of patients, whereas the other 
components had a more favourable pharmacokinetic profile. Patients 
with sub-therapeutic rifampicin concentrations had a higher APACHE 
II score and a lower estimated GFR. If confirmed in a larger study, our 
findings strongly support the use of IV rifampicin in addition to anti-TB 
drugs given by nasogastric tube in the critically ill TB patient.
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